Clarity Pharmaceuticals' prostate-cancer diagnostic could be highly differentiated from peers if its Phase 3 trial delivers on sensitivity and specificity, Bell Potter analysts say in a note. They tell clients that revenue timing remains highly uncertain and contingent on multiple factors, but that the Australia-listed clinical-stage radiopharmaceutical company looks to be well funded into FY 2025 and should be self-funding from FY 2026. Bell Potter cuts the stock's target price 7.1% to A$1.30 but maintains a speculative buy rating. ([email protected]; @StuartLCondie)
- Forums
- ASX - By Stock
- CU6
- Ann: Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
Ann: Positive Guidance from FDA on Phase 3 Prostate Cancer Trial, page-40
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
|
|||||
Last
$5.51 |
Change
0.420(8.25%) |
Mkt cap ! $1.712B |
Open | High | Low | Value | Volume |
$5.20 | $5.54 | $5.16 | $11.58M | 2.155M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 608 | $5.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.52 | 5458 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 8596 | 5.490 |
12 | 11654 | 5.480 |
6 | 9694 | 5.470 |
7 | 17568 | 5.460 |
6 | 5703 | 5.450 |
Price($) | Vol. | No. |
---|---|---|
5.510 | 454 | 2 |
5.520 | 2596 | 4 |
5.530 | 14985 | 4 |
5.540 | 15621 | 6 |
5.550 | 22915 | 6 |
Last trade - 14.46pm 11/07/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |